版本:
中国

BRIEF-Zymeworks' two bispecific immuno-oncology drug candidates have been nominated by Eli Lilly for late-stage, preclinical development

June 12 Eli Lilly And Co

* Zymeworks - two bispecific immuno-oncology drug candidates have been nominated by Eli Lilly for late-stage, preclinical development

* Zymeworks - Granted Lilly worldwide, royalty-bearing license to develop, commercialize bispecific therapeutic candidates toward Lilly's therapeutic targets Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐